ArticleBMC gastroenterology2025
The nomograph predicting the recurrence of Solid Pseudopapillary Neoplasm of the Pancreas: a study of the SEER database and a Chinese cohort.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid pseudopapillary neoplasm of the pancreas (SPN) represents a rare form of low-grade malignant pancreatic cystic neoplasm. This study seeks to construct a predictive nomograph model for SPN recurrence.
methodsData was collected from patients with SPN from the Surveillance, Epidemiology, and End Results (SEER) database in the United States from the years 2010 to 2021 as the training cohort. We collected data from our two hospitals as an external validation cohort from the years 2011 to 2021. Logistic regression analysis was used to analyze the related factors of recurrence, and a predictive nomograph model was established and verified. The calibration curve was plotted by the Bootstrap method, and the clinical efficacy of the model was evaluated by the decision curve analysis.
resultsThe SEER database included 455 patients. Five of them (1.10%) experienced recurrence, and the liver is the main recurrence site. There is a significant difference in tumor size (P = 0.001) between recurrent patients and the non-recurrent. Tumor size (P = 0.012) and regional nodes positive (P = 0.007) were independent predictors of relapse. We constructed a nomograph model based on them, the C-index 0.782 with a p-value 0.001. The C-index of the model in the external validation queue was 0.865 with a p-value 0.009. The calibration curve indicated that the model prediction probability is in well line with the actual observation probability, and decision clinical analysis showed a good net return.
conclusionThis constructed nomogram could well predict the possibility of SPN recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.